Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The firm likes the setup for 2025 with Auvelity IP overhang lifted and clearer visibility into a 2nd act with Symbravo approval and good AXS-05 data in Alzheimer’s disease agitation. Wells sees upside over the year with commercial performance and solriamfetol readouts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $167 from $143 at BofA
- Axsome Therapeutics price target raised to $195 from $137 at Mizuho
- TD ups Axsome target, sees takeout speculation on patent settlement
- Axsome Therapeutics initiated with a Buy at Deutsche Bank
- Axsome Therapeutics price target raised to $150 from $110 at Leerink